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Susceptibility testing of anidulafungin (AFG) against 32 mold isolates showed an excellent correlation
between disk diffusion (DD) and broth microdilution methods. Based on our data, a 2-g disk of AFG and
a 24-h reading time might represent the best parameters for AFG DD testing against filamentous fungi.
The number of invasive fungal infections, including systemic
infections caused by Aspergillus species, zygomycetes, and
other species of molds (Fusarium and Scedosporium) (3, 5, 11,
12, 15, 20, 23, 24, 26, 27), has risen over the last 20 years.
Recently, the novel echinocandin anidulafungin (AFG) has
been licensed and exhibits high antifungal activity (1, 4, 6, 7, 13,
21, 22, 28). Some investigators have explored the use of disk
diffusion (DD) susceptibility testing for caspofungin and AFG
against yeasts (specifically, Candida isolates) (9, 10, 14, 19), but
there is not much data available for AFG DD testing against
molds (2, 8). Therefore, in this study we compared the AFG
inhibition zones (IZs) determined via the DD assay with the
minimum effective concentrations (MECs) obtained by the broth
microdilution (BD) reference method to determine the best
correlation between the two methods. The study was con-
ducted at two university centers, and the intralaboratory re-
producibility and interlaboratory agreement results were eval-
uated. The AFG susceptibilities of 33 isolates were determined
by both the BD and DD assays. All assays were performed in
duplicate on two different days by each center. A total of 32
clinical mold isolates were tested (Aspergillus fumigatus, n  8;
Aspergillus flavus, n  6; Aspergillus terreus, n  4; Aspergillus
niger, n  3; Acremonium curvulum, n  1; Acremonium stric-
tum, n  1; Fusarium oxysporum; n  2; Fusarium dimerum, n 
2; Absidia corymbifera, n  2; Rhizopus oryzae, n  2; Scopu-
lariopsis brevicaulis, n  1). Candida krusei ATCC 6258 was
used as a quality control (QC). AFG was provided as a pure
powder form by Pfizer, Inc., and a stock solution was prepared
in dimethyl sulfoxide.
The BD method was performed as described in the
NCCLS M38-A document (16). Stock solutions for the QC
yeast isolate were prepared as described in the NCCLS
M27-A2 document (17). Conidial inocula and AFG were
prepared by using RPMI 1640 broth medium buffered to pH
7.0 with 0.165 M morpholinopropanesulfonic acid buffer.
The final concentrations of the antifungal agent in the mi-
crodilution trays ranged from 0.03 to 16 g/ml. Growth
(drug free) and sterility controls were included for each
tested isolate. Microdilution trays were incubated at 35°C,
and the AFG MECs, defined as the lowest drug concentra-
tions that produced growth of small, rounded, compact col-
onies compared to the hyphal growth of the control well
(19), were determined at 24 h for all the tested species.
Similarly, QC MICs were read at 24 h. The DD assays were
performed with homemade AFG disks. Blank disks that
were 6.3 mm in diameter (Becton Dickinson) were impreg-
nated with 20 l of AFG at final concentrations of 2, 5, 10,
and 25 g/disk and allowed to dry at room temperature. A
modification of the NCCLS M44-A DD method (18) for
yeast testing was performed to determine the diameters of
the antifungal IZs in millimeters at each center. The mold
inocula were prepared at optical densities ranging from 80
to 82% and from 68 to 70% transmittance for Aspergillus
species and the other species, respectively. A suspension
with a 0.5 McFarland standard was utilized for the QC
strain. Inoculum quantification was performed by counting
the number of CFU per milliliter of diluted inoculum on
Sabouraud dextrose agar plates. For the 32 mold isolates
and the one QC isolate, 94.5% of the inocula were within
the range of 1  106 to 5.0  106 CFU/ml, with higher
inoculum densities (6.20  106 to 3.57  108) observed for
eight isolates (three isolates of A. fumigatus, two of A. niger,
and two of R. oryzae). Mueller-Hinton agar plates supple-
mented with 2% dextrose and 0.5 l/ml methylene blue were
inoculated using sterile cotton swabs, and the antifungal
disks were applied to their surfaces. The plates were incu-
bated at 35°C, and IZs were measured at 24, 48, and 72 h.
The edges of the IZs were used as the points of marked
decrease in fungal density.
The comparative evaluation of the DD and BD methods
was performed by calculating the medians and the ranges of
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the IZ diameters and MECs. Pearson’s correlation coeffi-
cient was used to analyze the correlation between the MECs
and the DD zone diameters. The intralaboratory reproduc-
ibility and the interlaboratory agreement results were cal-
culated as the percentages of IZs with diameters within 3
mm of each other.
Table 1 summarizes the susceptibility results of AFG
against 33 fungal isolates, with MECs/MICs ranging from
0.03 to 16 g/ml. In general, isolates of Aspergillus spp.
proved to be highly susceptible to this new echinocandin, as
shown by a median MEC of 0.03 g/ml. Our data agree
with those reported by Messer et al. showing that AFG
MECs of 0.03 g/ml inhibited 100% of the tested isolates
(13). With the exception of S. brevicaulis, which showed a
median MEC of 0.03 g/ml, the other mold isolates tested,
including R. oryzae, A. corymbifera, Fusarium spp., and Acre-
monium spp., showed median MECs of 16 g/ml (range, 4
to 16 g/ml).
The disks embedded with AFG generated measurable IZs
for all Aspergillus species and for S. brevicaulis (Table 1).
Diameter sizes were distributed over a relatively narrow
range (from 11 to 23 mm). In general, as the AFG concen-
trations increased, so did the diameters of the IZs. Despite
the drug concentrations, we often observed microcolonies
inside the halos. These colonies were not considered in the
diameter measurements because their morphologies were
similar to the short, stubby hyphal branching observed at the
MEC (Fig. 1). Our data are in agreement with those re-
ported by Arikan et al., who found consistent intrazonal
growth in the halos of caspofungin disks when tested against
78 isolates of Aspergillus spp. (2).
According to the NCCLS BD results, the other mold isolates
belonging to four different genera (Rhizopus, Absidia, Fusar-
ium, and Acremonium) did not yield any measurable zone
diameters.
The Pearson’s correlation coefficient between the BD and
DD results was excellent, ranging from 0.928 to 0.943,
regardless of either the AFG concentrations or the reading
times.
We also observed reasonable intralaboratory reproduc-
ibility and interlaboratory agreement results, ranging from






IZ diam (mm) by DD method atb:
MEC (g/ml) by BD
24 h 48 h 72 h
Range Median Range Median Range Median Range Median
Aspergillus fumigatus (8) 2 13–18 16 13–17 14.5 13–17 14 0.03–0.06 0.03
5 15–19 17 11–18 16 14–18 15
10 17–21 18 16–21 17 15–21 17
25 17–22 19 13–20 19 17–22 19
Aspergillus flavus (6) 2 11–19 16 11–17 15 11–17 15 0.03 0.03
5 15–20 17 14–18 16 14–18 16
10 15–21 19 15–20 17.5 15–20 17
25 19–23 20 16–23 19.5 17–23 19
Aspergillus terreus (4) 2 14–19 16.5 13–18 15 13–18 15.5 0.03–0.06 0.03
5 16–19 18 14–18 17 14–18 17
10 18–22 20 16–20 18.5 16–21 19
25 19–23 21 17–21 19 17–22 20
Aspergillus niger (3) 2 13–18 15.5 13–16 15 13–16 14.5 0.03 0.03
5 15–19 17 15–17 16 15–18 16
10 17–20 19 15–18 17 15–19 17
25 19–22 20 16–20 18 16–19 18
Other molds (10)c 2 NZD NZD NZD NZD NZD NZD 4.0–16 16
5 NZD NZD NZD NZD NZD NZD
10 NZD NZD NZD NZD NZD NZD
25 NZD NZD NZD NZD NZD NZD
Scopulariopsis brevicaulis (1) 2 12–15 13 12–15 13.5 11–15 12 0.03 0.03
5 13–18 17 12–18 17 12–18 15
10 14–19 18 13–19 18 13–19 17.5
25 15–21 19.5 14–21 16.5 15–21 20
Candida krusei ATCC 6258 2 9–14 10.5 6–13 10.5 ND ND 0.03 0.03
5 11–15 13 11–14 12.5 ND ND
10 12–16 14.5 12–15 14 ND ND
25 15–17 16 13–16 15.5 ND ND
a Each isolate was tested in duplicate on two different days by each university center.
b NZD, no zone diameter; ND, not determined.
c Other molds included Acremonium curvulum (n  1), A. strictum (n  1), Fusarium oxysporum (n  2), Fusarium dimerum (n  2), Absidia corymbifera (n  2),
and Rhizopus oryzae (n  2).
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92.7 to 99.2% and from 81.5 to 92.7%, respectively (Ta-
ble 2).
Therefore, based on the overall data, a 2-g disk of AFG
and a 24-h reading time might represent the best parameters
for DD testing of AFG against filamentous fungi. These
testing conditions are preferred in order to lower the quan-
tity of drug necessary to perform the test and to lower the
time needed to read the plates. Being less time-consuming
and less labor-intensive, the DD method could be a good
alternative to the BD method. Further studies which include
a larger number of clinical filamentous fungi are warranted
to confirm our results.
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